Welcome to our dedicated page for Equillium SEC filings (Ticker: EQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Equillium, Inc. (Nasdaq: EQ) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Equillium is a clinical-stage biotechnology company based in La Jolla, California, focused on developing immunomodulatory therapies for severe autoimmune and inflammatory disorders, with its lead candidate EQ504 targeting the aryl hydrocarbon receptor (AhR).
Through this page, users can review Form 10-Q and 10-K reports, which include details on Equillium’s operating losses, cash resources, going concern language from auditors, and management’s discussion of risks and plans related to its immuno-inflammatory pipeline and financing needs. Form 8-K filings document material events such as private placement agreements to fund EQ504 development, amendments to at-the-market sale agreements, changes in independent registered public accounting firms, leadership and board updates, and the termination of collaboration and license agreements related to itolizumab with Biocon Limited.
Equillium’s filings also cover Nasdaq listing matters, including notices of non-compliance with minimum bid price requirements and subsequent confirmation of regained compliance. Additional disclosures describe the company’s adoption of a cryptocurrency treasury reserve strategy, amendments to its investment policy, and supplemental risk factors associated with digital asset holdings.
On Stock Titan, these documents are updated in near real time as they appear on EDGAR. AI-powered summaries help explain complex sections, highlight key points on topics such as EQ504 development plans, capital structure changes, and treasury strategy, and make it easier to identify items like equity issuances, open market sale agreements and auditor changes. Users can also quickly locate Form 4 and other ownership-related filings to track insider and major holder activity as it is reported.
Equillium, Inc. files its annual report describing a preclinical-stage biotechnology business focused on therapies for severe autoimmune and inflammatory disorders. The company’s lead program, EQ504, is an aryl hydrocarbon receptor modulator initially targeted for ulcerative colitis and other gastrointestinal and inflammatory lung diseases.
EQ302 is a first-in-class, orally delivered inhibitor of IL‑15 and IL‑21 being evaluated for celiac disease and other gastrointestinal indications. Equillium expanded its pipeline through acquiring Ariagen in October 2024 for EQ504 and Bioniz in February 2022 for EQ302 and related peptide platforms.
The company strengthened its balance sheet via an August 2025 private placement raising approximately $30.0 million and a March 2026 private placement raising approximately $35.0 million, with an additional potential $20.0 million second closing tied to clinical and stock price milestones. Management states existing cash and cash equivalents are expected to fund operations into 2029.
Equillium, Inc. reported fourth quarter and full-year 2025 results showing a shift to a development-stage model focused on its EQ504 program. Full-year 2025 revenue was $0 compared with $41.1M in 2024, reflecting the conclusion of prior Ono-related revenue.
Research and development expenses fell sharply to $12.8M from $37.4M, and general and administrative expenses declined to $10.8M from $11.9M. Despite lower operating costs, the full-year net loss widened to $22.4M, or $(0.39) per share, versus a $8.1M loss, or $(0.23) per share, in 2024, mainly because revenue dropped.
Cash, cash equivalents and short-term investments were $30.3M as of December 31, 2025, up from $22.6M a year earlier. Together with a $50M private placement announced in August 2025 and a $35M private placement in March 2026, the company believes it can fund planned operations into 2029. Equillium plans to initiate a Phase 1 proof-of-mechanism study of EQ504 in mid-2026, with data expected about six months later.
EQ, Inc. ownership disclosure: RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah report beneficial ownership of 6,480,209 shares, representing 9.9% of the outstanding common stock under a Beneficial Ownership Blocker.
The 9.9% figure is calculated using November 10, 2025 outstanding shares of 60,893,283, plus 1,179,508 shares issued in a private placement on March 13, 2026, and 3,383,873 shares issuable upon exercise of pre-funded warrants. The Fund holds 3,096,336 shares directly and pre-funded warrants exercisable for up to 17,698,593 shares; exercise is blocked to prevent ownership above 9.9%.
Equillium, Inc. senior vice president and COO Christine Zedelmayer exercised options to acquire 120,312 shares of common stock at an exercise price of $0.785 per share. She then sold 120,312 shares of common stock at a weighted average price of $2.5003 per share in open-market transactions effected under a Rule 10b5-1 trading plan adopted on August 27, 2025. Following these transactions, she directly holds 62,586 shares of Equillium common stock. The option exercised had been scheduled to vest over four years, with 25% on the first anniversary and the remainder in 36 equal monthly installments.
Form 144 notice: Christine Zedelmayer submitted a Rule 144 notice reporting proposed sales of Common Stock. The filing lists a proposed sale quantity of 120,312 shares dated 03/13/2026, and shows prior reported dispositions of 11,900 shares on 12/15/2025, 185,937 shares on 02/19/2026, and 181,219 shares on 03/09/2026.
Equillium, Inc. entered into a private placement with RA Capital Healthcare Fund to raise approximately $35.0 million through common stock and a pre-funded warrant. The company will sell 1,179,508 shares at $1.854 per share and a pre-funded warrant for up to 17,698,593 shares at $1.8539 per warrant share, with an exercise price of $0.0001 per share. The warrant is exercisable immediately on a cash or cashless basis, subject to a beneficial ownership cap of 19.99%. Equillium plans to use the net proceeds, together with existing cash, to fund development of EQ504 and for working capital and general corporate purposes. The company will also grant the investor registration rights to resell the shares and warrant shares, subject to potential cash penalties if registration obligations are not met.
Equillium, Inc. senior vice president and COO Christine Zedelmayer reported an exercise-and-sell set of transactions in company common stock. On February 19, 2026, she exercised options to acquire a total of 185,937 shares of common stock at prices of $0.785 and $0.73 per share.
On the same date, she sold the same 185,937 shares in open-market transactions at average prices of about $1.78 per share. After these trades, she directly held 91,444 shares of Equillium common stock. The filing notes that the sales were made under a Rule 10b5-1 trading plan adopted on August 27, 2025, indicating they were pre-arranged rather than timed discretionarily.
Equillium, Inc. senior vice president and COO Christine Zedelmayer exercised stock options and sold shares in a planned transaction. On March 9, 2026 she exercised options for a total of 152,361 shares of common stock at an exercise price of $0.785 per share.
The same day she sold 181,219 shares of common stock at a weighted average price of $2.00 per share, with individual sale prices ranging from $2.00 to $2.015, under a Rule 10b5-1 trading plan adopted on August 27, 2025. After these transactions she directly owned 62,586 shares of Equillium common stock.
Christine Zedelmayer reported sales of common stock under Rule 144. The filing lists four transactions dated 11/25/2025, 12/12/2025, 12/15/2025, and 02/19/2026 totaling 229,739 shares sold for aggregate proceeds of $377,658.
The transactions are reported on Form 144 and reflect dispositions from stock option-related and employee plan holdings referenced in the securities table.